1326P Combination of stereotactic ablative radiotherapy with anti-PD-1 in oligoprogressive disease: Final results of a prospective multicenter study

Abstract

Methods: CRISP (NCT02622581) is a prospective, observational, open, multicentre, interdisciplinary clinical research platform that collects data on all (sequential) treatments, patient and tumour chr, biomarker testing, clinical and patient-reported out in w180 hospitals and practices in Germany. Currently 6300+ pts were recruited, who will be followed until death or end of project. Data from 493 pts with PD-L1 TPS50% recruited between 12/2015 and 06/2019 and receiving CPI as 1 st -line treatment was analysed. Pts were deemed se if they had the following chr: ECOG¼0-1, Stage IV, no brain metastases, no HIV or second tumour and no prior (neo-)adjuvant therapies.Results: Of 473 analysed pts 191 pts were potentially se in reflection of inclusion criteria for clinical trials KEYNOTE 42 and 24, 282 pts were n-se representing the realworld pts population. Although both groups are similar in age (median 68 years, both) and CR/PR rates were comparable (1%[se] vs. 2%[n-se] and 21% vs. 22%) as well as rates of stopped treatments because of toxicity (10%, both), potentially se pts. had a longer PFS (10.

Immunotherapy Alone or in Combination with Stereotactic Body Radiotherapy in Advanced Lung Cancer: A Pooled Analysis of Randomized Clinical Trials

“…In oligoprogressive advanced disease (NSCLC and melanoma), IT (nivolumab) combined with SBRT had a 42% ORR with median PFS and OS of 14.2 and 37.4 months ( 18 ). Accordingly, SBRT to oligoprogressive lesions can improve local control and delay further disease progression in advanced lung cancer patients ( 19 ).…”